02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
20:27 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer; lung cancer Mouse studies suggest LPA could enhance the efficacy of chemotherapies and anti-PD-1 immunotherapies to treat brain and lung cancers. In a mouse model of glioma, LPA plus the generic chemotherapy...
18:09 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

Akcea's AKCEA-APO(a)-LRx reduces LPA levels in Phase II

Akcea Therapeutics Inc. (NASDAQ:AKCA) said AKCEA-APO(a)-LRx led to significant dose-dependent reductions in lipoprotein(a) (LPA) compared with placebo in a Phase II trial to reduce elevated LPA levels in patients with established cardiovascular disease. The company...
22:42 , Sep 21, 2018 |  BioCentury  |  Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
03:13 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Amgen's Repatha lowers LDL-C in Phase III for dyslipidemia in Type II diabetics

Amgen Inc. (NASDAQ:AMGN) reported in June that Repatha evolocumab met the co-primary endpoints in the Phase III BANTING trial to treat hypercholesterolemia or mixed dyslipidemia in Type II diabetics taking the maximum tolerated dose of...
16:10 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

Madrigal reports Phase II data of MGL-3196 for HeFH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) reported Phase II data for MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH) that, despite meeting the primary endpoint, suggest the candidate would be unable to compete with marketed drugs in...
21:13 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Athera begins Phase IIa trial of PC-mAb for arterial inflammation

Athera Biotechnologies AB (Stockholm, Sweden) began a Phase IIa trial of once-monthly IV PC-mAb to treat arterial inflammation in patients with elevated levels of lipoprotein(a) (LPA) . The double-blind, placebo-controlled, European trial's primary endpoint is...
19:54 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Madrigal completes enrollment in Phase II of MGL-3196 for HeFH

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) said it has enrolled 113 patients in a Phase II trial of MGL-3196 (VIA-3196) to treat heterozygous familial hypercholesterolemia (HeFH), exceeding its target enrollment of 105. The company said it would...
22:54 , Sep 14, 2017 |  BC Innovations  |  Targets & Mechanisms

Platelets YAP at cancer

While elevated platelet levels often signify an underlying malignancy, the molecular mechanisms linking the two are not well understood. Now, a team from MD Anderson has shown a well-known, but barely exploited signaling pathway mediates...
19:07 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

Regeneron reports Phase II data for evinacumab in HoFH

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from an open-label, international Phase II trial in 9 patients with homozygous familial hypercholesterolemia (HoFH) showing that evinacumab (REGN1500) added to current lipid-lowering therapy reduced mean LDL-C from baseline...